• linkedin
  • Increase Font
  • Sharebar

    Sunitinib vs. everolimus: PFS, toxicity differ in study

    Greater radiographic PFS with sunitinib, but lower toxicity observed with everolimus

    Durham, NC—In a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival (PFS) compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma (RCC) and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.

    Related: How renal mass biopsy impacts management

    Andrew Armstrong, MD, MScDr. Armstrong“Sunitinib resulted in improved PFS both in good- and intermediate-risk patients and papillary and unclassified histologies, whereas everolimus resulted in improved PFS in both poor-risk and chromophobe subtypes. Sunitinib and everolimus resulted in different rates of expected toxicities, with slightly more severe toxicities with sunitinib but more drug discontinuations due to toxicity from everolimus,” said Dr. Armstrong, co-director of the Genitourinary Oncology Research Program, Duke Cancer Institute, Durham, NC.

    Non-clear cell RCC is a genetically and histologically diverse collection of heterogeneous diseases that account for about 25% of kidney cancers, most commonly comprised of papillary types 1 and 2, chromophobe, and a group of diseases called unclassified carcinomas, each with varying prognoses.

    Published evidence from single-arm trials, uncontrolled case series, and expanded access studies supports a front-line standard of care systemic therapy. Evidence from individual studies supports an anti-vascular endothelial growth factor (VEGF) or anti-mTOR approach to non-clear cell RCC, “but the data are limited by heterogeneity across different risk groups and lines of therapy,” so conclusive evidence is therefore not strong, Dr. Armstrong said.

    Also see - Renal cancer follow-up: Find the happy medium

    He presented the study at the 2015 American Society of Clinical Oncology annual meeting in Chicago. Results were subsequently published in Lancet Oncology (2016; 17:378-88).

    Next: About the study

    Wayne Kuznar
    Wayne Kuznar is a contributor to Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available